FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one product on the market and a strong clinical stage pipeline of adult stem cell programs. The company's lead product, ChondroCelect®, for cartilage repair in the knee, is the first product to be approved and obtain national reimbursement in Europe. ChondroCelect is currently on the market in Belgium, the Netherlands, Spain, the UK and Finland and benefits from full national reimbursement in 3 of these countries.
TiGenix's stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. TiGenix’ eASC pipeline comprises 3 clinical stage assets:
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect, the company’s product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, through clinical development to central European registration as a medicinal product. ChondroCelect consists of characterized cultured chondrocytes derived from the patient’s own cartilage and is used for autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects. ChondroCelect received European marketing authorisation as the first Advanced Therapy Medicinal Product, indicated for repair of single symptomatic cartilage defects of the femoral condyle of the knee in adults.